MedTrace Logo

Cytokines as Diagnostic Markers of Pulpal Inflammation and Their Impact on the Outcome of Vital Pulp Therapy

NCT07261761 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-12-03

No results posted yet for this study

Summary

intervention eligible patients with teeth diagnosed with reversible or irreversible pulpits will go for vital pulp therapy and the other group will be patients will go for extraction of caries free teeth for orthodontic reasons, blood samples will be collected from both groups to analyze the level of cytokines IL-8 and IL-10 and it's relation with the success of the pulp therapy

Conditions

  • Reversible Pulpitis
  • Irreversible Pulpitis

Interventions

PROCEDURE

Vital pulp therapy

1. Full medical and dental history will be taken from each patient. 2. Clinical and radiographic examination (Cone beam computed tomography) for the offending tooth. 3. After anesthesia, Rubber dam is applied and complete caries removal will be done, deeply inside the cavity, the excavation will be done using low speed hand piece and excavator. 4. A blood sample will be taken from the bleeding pulp tissue on a cotton pellet for Molecular test. 5. After exposure, the pulp will be amputated to the level of the canal orifices (full pulpotomy) pulp vitality was confirmed by the presence of bleeding pulp tissue from all canals. 6. Putty MTA will gently place over the pulp. 7. The cavity will be sealed with initial deep layer of resin modified glass ionomer restoration (RMGI) and final superficial layer of composite restoration.

PROCEDURE

Extraction

1. Full medical and dental history will be taken from each patient. 2. Clinical and radiographic examination (Cone beam computed tomography) for the offending tooth. 3. After anesthesia, Rubber dam is applied. 4. A blood sample will be taken from the bleeding pulp tissue on a cotton pellet for Molecular test. 5. Extraction for orthodontic reasons.

PROCEDURE

blood sample collection

after access opening blood sample will be collected

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2024-10-01
Completion
2025-04-02

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07261761 on ClinicalTrials.gov